

TCT-458

Retrograde CTO PCI of Native Coronary Arteries via Left Internal Mammmary Artery Grafts: Insights from a Multicenter US Registry




Peter Tajti,¹ Dimitri Karpaliotis,² Khaldoon Alaswad,³ Farouc Amin Jaffer,⁴ Robert Yeh,⁵ Mitul Patel,⁶ Ehtisham Mahmud,⁶ James Choi,⁷ Nicholas Burke,⁸ Anthony Doing,⁹ Catalin Toma,¹⁰ Barry Uretsky,¹¹ Elizabeth Holper,¹² R. Michael Wyman,¹³ William Lombardi,¹⁴ David Kandzari,¹⁵ Nicholas Lembo,¹⁶ Santiago Garcia,¹⁷ Oleg Krestyanirov,¹⁸ Dmitrii Khelinskii,¹⁸ Michail Koutouzis,¹⁹ Ioannis Tsiafoutis,¹⁹ Jeffrey Moses,² Ajay Jayant Kirtane,²⁰ Manish Parikh,² Ziad Ali,² Raja Hatem,²¹ Aris Karatasakis,²² Judit Karacsonyi,²³ Barbara Anna Danek,²⁴ Bavana Rangan,²⁵ Emmanouil Brilakis²⁶

¹Minneapolis Heart Institution, Abbott Northwestern Hospital; University of Szeged, Minneapolis, Minnesota, United States; ²NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States; ³Henry Ford Hospital, Detroit, Michigan, United States; ⁴Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, United States; ⁵Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; ⁶VA San Diego Healthcare System and University of California San Diego, La Jolla, California, United States; ⁷Baylor University Medical Center, Dallas, Texas, United States; ⁸Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota, United States; ⁹Medical Center of the Rockies, Loveland, Colorado, United States; ¹⁰Heart and Vascular Institute, UPMC Presbyterian, Pittsburgh, Pennsylvania, United States; ¹¹University of Arkansas for Medical Sciences/Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States; ¹²The Heart Hospital Baylor Plano, Plano, Texas, United States; ¹³Torrance Memorial Medical Center, Torrance, California, United States; ¹⁴University of Washington Medical Center, Seattle, Washington, United States; ¹⁵Piedmont Heart Institute, Atlanta, Georgia, United States; ¹⁶Columbia University, New York, New York, United States; ¹⁷University of Minnesota, Minneapolis, Minnesota, United States; ¹⁸E.N. Meshalkin Siberian Federal Biomedical Research Center, Ministry of Health Care of Russian Federation, Novosibirsk, Russian Federation; ¹⁹2nd Cardiology Department of Hellenic Red Cross Hospital, Athens, Greece; ²⁰Columbia University / New York-Presbyterian Hospital, New York, New Jersey, United States; ²¹Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada; ²²Dallas VAMC and UT Southwestern, Dallas, Texas, United States; ²³UT Southwestern Medical Center, Dallas, VA North Texas Healthcare System, University of Szeged, Dallas, Texas, United States; ²⁴Dallas VA Medical Center/UT Southwestern, Dallas, Texas, United States; ²⁵UT Southwestern Medical Center/ VA North Texas Health Care System, Dallas, Texas, United States; ²⁶Minneapolis Heart Institute, UT Southwestern Medical Center/VA North Texas Health Care System, Minneapolis, Minnesota, United States

BACKGROUND Retrograde percutaneous interventions (PCI) of native coronary artery chronic total occlusions (CTOs) via left internal mammmary artery (LIMA) grafts have received limited study.

METHODS We compared the clinical and procedural characteristics and outcomes of retrograde CTO PCI through LIMA grafts vs. via other vessels in a contemporary multicenter registry.

RESULTS The LIMA was used as collateral channel in 20 of 990 retrograde CTO PCIs (2.0%) performed at 18 US Centers. The mean age of the study patients was 69±7 years, and 95% were men. The most common CTO target vessel was the right coronary artery (55%). The mean J-CTO score in the LIMA group was high (3.45±0.76). The technical and procedural success rate of retrograde PCI via LIMA grafts was 70% and 70%, respectively, vs. 81.0% and 78.2% (p=0.247, and p=0.412), respectively for retrograde via other conduits (Figure). The incidence of major in-hospital complications was also similar between the LIMA and non-LIMA retrograde groups (5% vs. 6%, p=1.000). Use of guide catheter extensions (40% vs. 28%, p=0.217), intravascular ultrasound (45% vs. 31%, p=0.197), and left ventricular assist devices (24% vs. 10%, p=0.769) were numerically higher in retrograde CTO PCIs via LIMA grafts.



CONCLUSION Retrograde CTO PCI is infrequently performed via LIMA grafts and is associated with numerically lower success but similar major in-hospital complication rates as retrograde CTO PCI performed via other vessels.

CATEGORIES CORONARY: PCI Outcomes

TCT-459

Simple vs complex strategy for the treatment of bifurcation lesions in the context of a coronary chronic total occlusion. A multicenter registry



Soledad Ojeda,¹ Lorenzo Azzalini,² Jorge Chavarria Viquez,¹ Antonio Serra,³ Francisco Hidalgo,⁴ Susanna Benincasa,⁵ Livia L. Gheorghe,³ Roberto Diletti,⁶ Miguel Romero,¹ Barbara Bellini,⁵ Alejandro Gutierrez-Barríos,⁷ Javier Suarez De Lezo,⁴ José Segura,¹ Mauro Carlino,⁵ Antonio Colombo,⁸ Manuel Pan¹


¹Reina Sofia Hospital, Córdoba, Spain; ²Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Milan, Italy; ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; ⁴Reina Sofia Hospital, Cordoba, Spain; ⁵San Raffaele Scientific Institute, Milan, Milan, Italy; ⁶Thorax Center, Erasmus MC, Rotterdam, Netherlands; ⁷Hospital Puerta del Mar, Cádiz, Spain; ⁸San Raffaele Scientific Institute, Milan, Italy

BACKGROUND Little evidence exists regarding the optimal strategy for bifurcation lesions (BLs) in the context of a coronary chronic total occlusion (CTO). Our study aim was to compare the procedural and mid-term outcomes of patients with BLs in CTO treated with provisional stenting (simple approach) versus 2-stent techniques (complex strategy) in a multicenter registry.

METHODS Between January 2012 and June 2016, 922 CTO in 905 patients were successfully recanalized at the 4 participating centers. Of those, 238 patients with 238 CTO (25.8%) and a BL (Side branch ≥2mm located proximally, distally or within the occluded segment) were treated by a simple approach (n=201) or complex strategy (n=37). Propensity score matching (PSM) was performed to account for selection bias between both groups and 37 matched pairs were generated. Standardized differences were calculated for all covariates before and after matching to assess balance after matching (Figure). Technical success of CTO recanalization was defined as a residual stenosis <30% with TIMI flow grade III in the main vessel. Bifurcation technical success was considered to occur when a residual stenosis of <30% in the main vessel and a final TIMI flow grade III in both branches were obtained. Procedural success was defined as angiographic success plus the absence of in-hospital adverse events. Major adverse cardiac events (MACE) on follow-up were a composite of cardiac death, myocardial infarction, and clinical-driven target lesion revascularization.

RESULTS Angiographic and procedural success were comparable in the simple vs. complex group (94.5% vs 97.3%, p=0.48; and 85.6% vs 81.1%, p=0.49). In all cases, bifurcation technical failure was due to a TIMI flow at the side branch <III. However, contrast volume, radiation dose and fluoroscopy time were lower in the simple approach. At follow-up (median of 25 months), MACE rate was 8% in the simple and 10.8% in the complex group (p=0.58). There was a trend towards a lower MACE-free survival in the complex group (80.1% vs 69.8%,

p=0.08). After PSM, there were no differences between groups with regard to immediate and follow-up results, although a complex strategy was associated with worse procedural metrics (Contrast volume (ml): 367±111 vs 301±103, p< 0.01; radiation (Gy/cm2): 452.8±208.1 vs 354.1±303.7, p= 0.04; fluoroscopy time (min): 61.2±27.7 vs 47.7±28.9, p= 0.04).



CONCLUSION BLs in CTO can be approached as is done for regular BLs, for which provisional stenting is considered the technique of choice. After PSM, there were no differences in procedural and mid-term clinical outcomes between simple and complex strategies.

CATEGORIES CORONARY: PCI Outcomes

TCT-460

Clinical Impact of Complete Coronary Revascularization by Percutaneous Coronary Intervention in Patients with Chronic Total Occlusion in the First and Newer Drug-Eluting Stent Generation Era



Renato Valenti,¹ Angela Migliorini,¹ Andrea Bernardini,¹ Maria Grazia De gregorio,¹ Raffaele Martone,¹ Maria Raffaella Aicale,¹ Sofia Morini,² Ruben Vergara,³ Martina Berteotti,⁴ Nazario Carrabba,⁵ David Antoniucci¹
¹Careggi Hospital, Florence, Florence, Italy; ²Division of Cardiology - Careggi Hospital, Florence, Florence, Italy; ³Division of Cardiology Careggi Hospital, Florence, Florence, Italy; ⁴Careggi Hospital, Florence, Florence, Italy; ⁵Division of Cardiology, Florence, Florence, Italy

BACKGROUND Large data have shown that complete coronary revascularization is associated with an improvement prognosis in term of mortality in patients with multivessel disease. Moreover different studies suggest that the newer generation of drug-eluting stent (DES) performs better in term of procedural results and composite cardiovascular events than the first generation of DES. The aim of this study is to evaluate the clinical impact in term of mortality of complete coronary revascularization by PCI in a “real world” patients with chronic total occlusion (CTO) in the first and the newer generation DES era.

METHODS From the Florence CTO-PCI registry all consecutive patients who underwent a PCI for CTO from 2003 to 2015. Patients with successful PCI received DES. Patients were divided in two groups according to the first (2003-2008) and newer (2009-2015) generation DES era. First generation DES: Sirolimus eluting stent (Cypher; Cordis Corp., Miami Lakes, Florida, USA) and Paclitaxel eluting stent (Taxus®; Boston Scientific, Natick, MA, USA). Second generation DES: Everolimus eluting stent (Xience V®, Abbott Vascular, CA, USA) and Promus Element, Boston Scientific, Natick, Massachusetts USA). Cardiac survival analysis was performed by Kaplan-Meier method. The independent predictors associated with long-term cardiac mortality were assessed by Cox multivariable analysis. Interaction analysis was performed by multivariable analysis.

RESULTS Overall, 1396 patients underwent a CTO-PCI attempt; n=682 (49%) in the first generation DES era, while n=714 (51%) in the newer generation DES era. Successful CTO-PCI was higher in the new generation DES era than the first one (84% vs. 73%; p<0.001) and as a consequence a complete coronary revascularization was achieved more frequently in the newer DES era (73% vs 62%; p<0.001). Long-term mortality rate (3 years) was similar between patients treated in the first and in the newer DES era (91 ± 1.2% vs. 94 ± 1.0%; p=0.23). By multivariable analysis the adjusted complete revascularization was

strongly and inversely related with long-term mortality (HR 0.33; p<0.001). No interaction was found between complete revascularization and the generation DES era (p=0.206).

CONCLUSION As expected, the newer DES era is associated with an improvement of successful CTO-PCI driven by development in technique, technology, strategy and operator’s skill. Anyway, when a complete coronary revascularization was achieved whatever the DES era, the clinical benefit in term of mortality was strong and similar.

CATEGORIES CORONARY: Stents: Drug-Eluting

NOVEL MITRAL VALVE THERAPIES

Abstract nos: 461 - 465

TCT-461

6 Month Outcomes of Transcatheter Annular Reduction Therapy (TART) with the ARTO™ System for Functional Mitral Regurgitation



Stephen G. Worthley,¹ Andrejs Erglis,² Simon Redwood,³ David Hildick-Smith,⁴ Tony Rafter,⁵ Alan Whelan⁶
¹Genesis Healthcare, Sydney, Victoria, Australia; ²P. Stradins Clinical University Hospital, Riga, Latvia; ³St Thomas’ Hospital, London, United Kingdom; ⁴Royal Sussex County Hospital, Brighton, United Kingdom; ⁵The Wesley Hospital, Brisbane, Queensland, Australia; ⁶Mount Hospital, Perth, Western Australia, Australia

BACKGROUND The ARTO™ System (MVRx, San Mateo, CA) is a Transcatheter Annular Repair Therapy (TART) that modifies the mitral annulus to improve leaflet coaptation in patients with functional mitral regurgitation and systolic heart failure. The MAVERIC trial was designed to evaluate the safety and performance of the ARTO™ System in these patients.

METHODS MAVERIC is a prospective, single arm study conducted in 8 sites in 4 countries and has enrolled 45 patients. Key inclusion criteria are symptomatic systolic HF with NYHA Class II-IV and FMR grade ≥ 2+. Exclusion criteria consist of clinical variables that preclude feasibility of the ARTO procedure and significant structural abnormality of the valve. Primary outcomes are the major adverse event rate at 30 days post-procedure, MR grade change from baseline to 30 days and procedural device success. Additional planned clinical/echo follow-up is at 180 days and yearly for 3 years. Clinical outcomes are CEC adjudicated and all echo parameters are analyzed by an echo core lab. 30 day data on 45 patients was presented at EuroPCR 2017. This presentation will report the 6 month follow-up on these patients.

RESULTS At baseline, mean age of the patients is 70 +12, 60% are male, LVEF 40 +9, prior PCI 33%, prior MI 38%, atrial fibrillation 44% and COPD 21%. Results to date: 30 day outcomes on 45 patients include 0 deaths, 0 myocardial infarctions and 0 strokes and 100% device technical success including no incidence of LCX compression. There were 2 major adverse events in the first 30 days: a pericardial effusion which was surgically drained without recurrence and one acute kidney injury post-procedure which has resolved without sequelae. From baseline to 30 days, there were meaningful improvements in MR, LV volumes and functional measures. 71% of patients had MR grade 3+/4+ at baseline and at 30 days 86% were Grade 0 to 2+ (p<0.0001). Regurgitant volume decreased from 43.1 ± 12.1 to 23.6 ± 9.7ml. (p<0.0001). NYHA functional class status improved from 71% in Grade III/IV at baseline to 73% in Class I and II at 30 days. Currently, all of these measures are stable or improved out to 3 years.

CONCLUSION The MAVERIC trial establishes the safety and efficacy of the ARTO system in the treatment of FMR associated with systolic HF. Key highlights of the study include a very low rate of adverse events accompanied by structural improvements in cardiac function and clinical status.

CATEGORIES STRUCTURAL: Valvular Disease: Mitral

TCT-462

Two-years Echocardiographic Changes After Neochord Procedure



Andrea Colli,¹ Laura Besola,² Erica Manzan,² Eleonora Bizzotto,³ Roberto Bellu,³ Nicola Pradegan,³ Alessandro Fiocco,³ Matteo Nadali,³ Demetrio Pittarello,³ Gino Gerosa²
¹University of Padova, Padova, Padua, Italy; ²University of